NEW YORK (AP) -- Amgen Inc. and Takeda Pharmaceutical Company Ltd. said Wednesday that their potential cancer treatment motesanib failed to meet its key goal in a late-stage study focusing on lung cancer patients.
The drug candidate failed to improve overall survival rates for patients with non-squamous non-small cell lung cancer. Squamous refers to the type of cells from which the cancer originated. The study involved 1,090 patients receiving combination of the drug candidate and chemotherapy or a combination of chemotherapy and placebo. In 2008, the companies halted the study after early data showed higher mortality rates among patients receiving motesanib than among patients receiving a placebo.